Stocktoria

Mirum Pharmaceuticals, Inc. MIRM

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-07-18
Chart by TradingView
4/9
Piotroski F — financial health
0.54
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Valuation · market cap as of 2026-06-29

Market cap$7.5B
P / S14.5×
P / B24.0×
P / FCF137.5×

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$521.3M$336.9M$186.4M$77.1M$19.1M
Operating income-$22.1M-$87.6M-$109.2M-$131.2M-$173.4M
Net income-$23.4M-$87.9M-$163.4M-$135.7M-$84.0M
Operating cash flow$55.8M$10.3M-$70.9M-$120.1M-$132.8M
Free cash flow$54.9M$9.3M-$71.1M-$120.4M-$132.8M
Total assets$842.8M$670.8M$646.6M$352.9M$294.7M
Total liabilities$528.1M$445.1M$398.0M$210.9M$174.4M
Shareholders' equity$314.7M$225.6M$248.7M$142.0M$120.2M
Ratios
Operating margin-4.2%-26.0%-58.6%-170.3%-906.1%
Net margin-4.5%-26.1%-87.7%-176.0%-438.9%
FCF margin10.5%2.8%-38.1%-156.3%-693.8%
Return on assets-2.8%-13.1%-25.3%-38.4%-28.5%
Return on equity-7.4%-39.0%-65.7%-95.5%-69.9%
Current ratio2.673.104.452.943.91
Revenue growth54.7%80.8%141.8%302.7%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC582,085$53.8M
Point72 Asset Management, L.P.353,591$32.7M

Why these scores methodology →

Piotroski F-score: 4/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 0.54 (distress)

  • Working capital / assets 0.408
  • Retained earnings / assets -0.792
  • EBIT / assets -0.026
  • Equity / liabilities 0.596

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001759425 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.